Durga Shankar Meena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Durga Shankar Meena has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
Deepak Kumar
Division of Infectious Diseases (Department of General Medicine), All India Institute of Medical Sciences, Jodhpur, India
27 shared publicationsGopal Krishana Bohra
Division of Infectious Diseases (Department of General Medicine), All India Institute of Medical Sciences, Jodhpur, India
25 shared publications- Deepak Kumar
Department of Medicine and Infectious Diseases, All India Institute of Medical Science , Jodhpur, Rajasthan
22 shared publications - Gopal Krishana Bohra
Department of General Medicine, All India Institute of Medical Sciences, Jodhpur, India
13 shared publications Mahendra Kumar Garg
Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, India
11 shared publications- Mahendra Kumar Garg
Department of General Medicine, All India Institute of Medical Sciences, Jodhpur, India
10 shared publications
Latest Publications
- 15 October 2026
- Published by Springer Nature in Infection
- p. 1-10
Serum hepcidin as a host-derived biomarker of disease severity and risk stratification in tuberculosis
- 15 October 2026
- Published by Springer Nature in Infection
- p. 1-10
Serum hepcidin as a host-derived biomarker of disease severity and risk stratification in tuberculosis
- 21 September 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (5) , e70181
Caution in the Bag: A Sheet‐Like Deposit as a Visual Clue to Systemic Derangement in Immune‐Mediated TTP
- 21 September 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (5) , e70181
Caution in the Bag: A Sheet‐Like Deposit as a Visual Clue to Systemic Derangement in Immune‐Mediated TTP
- Open Access
- 12 August 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Persistent Staphylococcus aureus bacteremia and 30-day mortality: a systematic review and meta-analysis
- 12 August 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Open AccessPersistent Staphylococcus aureus bacteremia and 30-day mortality: a systematic review and meta-analysis
- 18 July 2026
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 63, 101228
Uncommon pathogen, fatal consequence: Abiotrophia defectiva infective endocarditis
- 18 July 2026
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 63, 101228
Uncommon pathogen, fatal consequence: Abiotrophia defectiva infective endocarditis
- Open Access
- 29 June 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Impact of methicillin resistance on mortality in Staphylococcus aureus endocarditis: a systematic review and meta-analysis
Background Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a leading cause of endocarditis with poor outcomes. The magnitude and consistency of its mortality risk compared with methicillin-susceptible S. aureus (MSSA) remain uncertain. Methods Data were extracted from PubMed, Embase, Scopus, and Cochrane Library from database inception to 30 November 2025, without language restrictions. A random-effects model (Restricted Maximum-Likelihood) was used to calculate pooled risk ratios (RRs). Heterogeneity was explored by stratified and meta-regression analyses. Publication bias was assessed using funnel plot symmetry and Egger’s regression. Results Twenty-four studies, comprising 3291 patients (1,011 with MRSA and 2280 with MSSA), met the inclusion criteria. Pooled short-term mortality was significantly higher in MRSA endocarditis (30.9% vs 25.6%; RR 1.48, 95% CI 1.21-1.80; I² = 34%). Across stratified analyses by study design, setting, region, and study era, mortality remained consistently higher in MRSA endocarditis. No significant differences were found for heart failure (RR 1.08, 95% CI 0.90-1.30), embolic events (RR 0.82, 95% CI 0.51-1.33), stroke (RR 0.88, 95% CI 0.78-1.00), or surgery performed (RR 0.97, 95% CI 0.56-1.68) in MRSA and MSSA groups. No publication bias was revealed by Funnel-plot inspection and Egger’s test (p = 0.082). Meta-regression showed no effect modification by age, hospital-acquired infection, prosthetic valve, or right-sided endocarditis. Conclusions MRSA endocarditis carries a significantly higher short-term mortality than MSSA, consistent across study designs and study-level characteristics. The major complications were comparable between the two groups.
- 29 June 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessImpact of methicillin resistance on mortality in Staphylococcus aureus endocarditis: a systematic review and meta-analysis
Background Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a leading cause of endocarditis with poor outcomes. The magnitude and consistency of its mortality risk compared with methicillin-susceptible S. aureus (MSSA) remain uncertain. Methods Data were extracted from PubMed, Embase, Scopus, and Cochrane Library from database inception to 30 November 2025, without language restrictions. A random-effects model (Restricted Maximum-Likelihood) was used to calculate pooled risk ratios (RRs). Heterogeneity was explored by stratified and meta-regression analyses. Publication bias was assessed using funnel plot symmetry and Egger’s regression. Results Twenty-four studies, comprising 3291 patients (1,011 with MRSA and 2280 with MSSA), met the inclusion criteria. Pooled short-term mortality was significantly higher in MRSA endocarditis (30.9% vs 25.6%; RR 1.48, 95% CI 1.21-1.80; I² = 34%). Across stratified analyses by study design, setting, region, and study era, mortality remained consistently higher in MRSA endocarditis. No significant differences were found for heart failure (RR 1.08, 95% CI 0.90-1.30), embolic events (RR 0.82, 95% CI 0.51-1.33), stroke (RR 0.88, 95% CI 0.78-1.00), or surgery performed (RR 0.97, 95% CI 0.56-1.68) in MRSA and MSSA groups. No publication bias was revealed by Funnel-plot inspection and Egger’s test (p = 0.082). Meta-regression showed no effect modification by age, hospital-acquired infection, prosthetic valve, or right-sided endocarditis. Conclusions MRSA endocarditis carries a significantly higher short-term mortality than MSSA, consistent across study designs and study-level characteristics. The major complications were comparable between the two groups.
- 14 June 2026
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 419, 579001
Short-term neurocognitive changes among people living with HIV assessed using the International HIV Dementia Scale
- 14 June 2026
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 419, 579001
Short-term neurocognitive changes among people living with HIV assessed using the International HIV Dementia Scale
- Open Access
- 29 May 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Association of procalcitonin levels with multidrug-resistant bloodstream infections: a prospective cohort study
Procalcitonin (PCT) is widely used for early detection of bloodstream infections. However, limited data correlate PCT levels with infection aetiology, especially in identifying multidrug-resistant (MDR) pathogens. This prospective study included patients with bloodstream infections (BSIs) from January 2022 to April 2024. Patients with positive blood cultures and simultaneous PCT testing were enrolled. The primary objective was to evaluate the association between PCT levels and MDR bacteremia. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of PCT. A total of 317 patients with positive blood cultures met the inclusion criteria. Of these, 186 (58.7%) had MDR bacteremia, while 131 (41.3%) were due to non-MDR pathogens. Gram-negative (GN) bacteremia accounted for 238 cases, and Gram-positive (GP) bacteremia for 79 cases. Median PCT values were significantly higher in MDR bacteremia (9.6, IQR: 3.4-17.1 ng/mL) compared to non-MDR (1.5, IQR: 0.5-4 ng/mL, p < 0.001). ROC analysis showed an area under the curve (AUC) of 0.71 for PCT and 0.47 for CRP in predicting MDR bacteremia. For GN bacteremia prediction, the AUC was 0.61 for PCT and 0.39 for CRP. PCT values were highest in urinary tract infections, followed by pneumonia and soft tissue infections (11.75, 5.65, and 5.1 ng/mL, respectively). PCT demonstrated moderate ability to discriminate MDR bacteremia. However, these results do not support its use as a standalone marker and must be interpreted with clinical and microbiological findings.
- 29 May 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessAssociation of procalcitonin levels with multidrug-resistant bloodstream infections: a prospective cohort study
Procalcitonin (PCT) is widely used for early detection of bloodstream infections. However, limited data correlate PCT levels with infection aetiology, especially in identifying multidrug-resistant (MDR) pathogens. This prospective study included patients with bloodstream infections (BSIs) from January 2022 to April 2024. Patients with positive blood cultures and simultaneous PCT testing were enrolled. The primary objective was to evaluate the association between PCT levels and MDR bacteremia. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of PCT. A total of 317 patients with positive blood cultures met the inclusion criteria. Of these, 186 (58.7%) had MDR bacteremia, while 131 (41.3%) were due to non-MDR pathogens. Gram-negative (GN) bacteremia accounted for 238 cases, and Gram-positive (GP) bacteremia for 79 cases. Median PCT values were significantly higher in MDR bacteremia (9.6, IQR: 3.4-17.1 ng/mL) compared to non-MDR (1.5, IQR: 0.5-4 ng/mL, p < 0.001). ROC analysis showed an area under the curve (AUC) of 0.71 for PCT and 0.47 for CRP in predicting MDR bacteremia. For GN bacteremia prediction, the AUC was 0.61 for PCT and 0.39 for CRP. PCT values were highest in urinary tract infections, followed by pneumonia and soft tissue infections (11.75, 5.65, and 5.1 ng/mL, respectively). PCT demonstrated moderate ability to discriminate MDR bacteremia. However, these results do not support its use as a standalone marker and must be interpreted with clinical and microbiological findings.
- 18 May 2026
- Published by Springer Nature in Infection
Combination antibiotic therapy in Staphylococcus aureus endocarditis: evidence, controversies, and future directions
Staphylococcus aureus is now the leading cause of infective endocarditis (IE) worldwide and is associated with high mortality and frequent complications. Combination antimicrobial therapy has long been proposed to enhance bactericidal activity, improve biofilm penetration, and limit resistance; however, its true clinical value remains uncertain. This narrative review examines the experimental and clinical evidence for combination regimens in Staphylococcus aureus infective endocarditis (S. aureus IE). We searched PubMed, Embase, Scopus, Web of Science, and the Cochrane Library through September 2025 for randomised trials, comparative observational studies, major guidelines, and key experimental reports. Evidence is synthesised across methicillin-susceptible and methicillin-resistant strains, and across native and prosthetic valve disease. We summarise the biological rationale, potential benefits, and stewardship impact of combination therapy. We also highlight the practical implications for when to consider, avoid, or de-escalate combination therapy, and outline priorities for future research. We find that evidence for combination therapy in S. aureus endocarditis remains limited and largely observational. Adjunctive rifampin and aminoglycosides have not shown consistent clinical benefit and are associated with increased toxicity. Beta-lactam combinations with vancomycin or daptomycin may reduce the bacteremia duration, but this has not translated into improved survival. Emerging regimens, particularly daptomycin combined with ceftaroline show promise in persistent bacteremia, although evidence remains observational. Overall, current data do not support routine use of combination therapy and favour a selective, case-based approach. High-quality multicentre studies integrating microbiological, pharmacodynamic, and clinical endpoints are urgently needed to define optimal combination strategies.
- 18 May 2026
- Published by Springer Nature in Infection
Combination antibiotic therapy in Staphylococcus aureus endocarditis: evidence, controversies, and future directions
Staphylococcus aureus is now the leading cause of infective endocarditis (IE) worldwide and is associated with high mortality and frequent complications. Combination antimicrobial therapy has long been proposed to enhance bactericidal activity, improve biofilm penetration, and limit resistance; however, its true clinical value remains uncertain. This narrative review examines the experimental and clinical evidence for combination regimens in Staphylococcus aureus infective endocarditis (S. aureus IE). We searched PubMed, Embase, Scopus, Web of Science, and the Cochrane Library through September 2025 for randomised trials, comparative observational studies, major guidelines, and key experimental reports. Evidence is synthesised across methicillin-susceptible and methicillin-resistant strains, and across native and prosthetic valve disease. We summarise the biological rationale, potential benefits, and stewardship impact of combination therapy. We also highlight the practical implications for when to consider, avoid, or de-escalate combination therapy, and outline priorities for future research. We find that evidence for combination therapy in S. aureus endocarditis remains limited and largely observational. Adjunctive rifampin and aminoglycosides have not shown consistent clinical benefit and are associated with increased toxicity. Beta-lactam combinations with vancomycin or daptomycin may reduce the bacteremia duration, but this has not translated into improved survival. Emerging regimens, particularly daptomycin combined with ceftaroline show promise in persistent bacteremia, although evidence remains observational. Overall, current data do not support routine use of combination therapy and favour a selective, case-based approach. High-quality multicentre studies integrating microbiological, pharmacodynamic, and clinical endpoints are urgently needed to define optimal combination strategies.
- Open Access
- 24 March 2026
- Published by Elsevier in Indian Heart Journal
- Vol. 78 (5) , 232-237
Revisiting Non-HACEK Gram-Negative Endocarditis: Emerging Clinical and Microbiological Trends from a Prospective Cohort
- 24 March 2026
- Published by Elsevier in Indian Heart Journal
- Vol. 78 (5) , 232-237
Open AccessRevisiting Non-HACEK Gram-Negative Endocarditis: Emerging Clinical and Microbiological Trends from a Prospective Cohort